Efficacy of mitomycin-c on success of primary external DCR surgery

---

Original Article

Author Details : Ram Kumar, Richa Shrivastava

Volume : 3, Issue : 4, Year : 2017

Article Page : 293-295

Suggest article by email

Get Permission

---

Abstract

Purpose: to evaluate effectiveness of mitomycin-C (MMC) application intraoperatively in cases of primary external dacryocystorhinostomy (EXT-DCR).
Materials and Methods: a total of 96 patients with primary acquired nasolacrimal duct obstruction (PANLDO) were included in a prospective, double-masked, randomized, controlled trial. 50% of patients underwent conventional DCR and 50% underwent intraoperative MMC (0.2mg/ml) application for 5 minutes in the standard DCR procedure. Patients were regularly followed-up. Final outcome at one year of follow-up was used to define success of the surgery. Both subjective decrease in watering and objective patency on syringing were assessed.
Both the patients and the researchers who were assessing the study outcomes were masked to treatment group.
Results: Mean age (SD) of patient was 43.88 (10.51) years. Success rate achieved with DCR procedure with MMC was 97.92% compared to 91.67% with DCR alone. No local or systemic side effects of MMC were found. The success rate was greater in the MMC group than the control group.
Conclusions: Adjunctive intraoperative MMC application with standard DCR surgery has a higher success rate than standard DCR surgery alone. Further larger, randomized studies are needed to confirm these findings.

Keywords: Dacryocystorhinostomy, Mitomycin C, Nasolacrimal duct obstruction.

How to cite : Kumar R, Shrivastava R, Efficacy of mitomycin-c on success of primary external DCR surgery. IP Int J Ocul Oncol Oculoplasty 2017;3(4):293-295

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.